CSPC Pharmaceutical Group Limited (CSPCY)

CSPC Pharmaceutical Group Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	6,777	12,015	10,298	9,284	7,296
Short-Term Investments	1,307	1,750	4,268	2,024	2,019
Cash & Short-Term Investments	8,084	13,765	14,566	11,307	9,316
Cash Growth	-41.27%	-5.50%	28.82%	21.38%	61.67%
Accounts Receivable	9,555	9,712	6,736	6,508	4,533
Other Receivables	745.45	129.53	100.05	39.78	129.68
Receivables	10,301	9,841	6,836	6,549	4,745
Inventory	3,337	3,139	2,555	2,480	1,861
Other Current Assets	166.11	-	-	-	-
Total Current Assets	21,888	26,745	23,957	20,337	15,921
Property, Plant & Equipment	12,503	11,643	10,977	9,564	8,934
Long-Term Investments	3,937	4,596	3,720	3,323	2,710
Goodwill	234.9	234.9	234.9	149.98	149.98
Other Intangible Assets	2,610	2,146	1,872	425.87	494.6
Long-Term Deferred Tax Assets	250.3	186.78	113.03	43	117.47
Long-Term Deferred Charges	-	52.53	35.81	41.98	14.15
Other Long-Term Assets	2,966	678.51	859.31	857.51	1,728
Total Assets	44,389	46,282	41,770	34,742	30,070
Accounts Payable	2,613	2,889	2,206	1,770	1,359
Accrued Expenses	137.51	7.55	3,922	3,166	2,337
Short-Term Debt	-	441.27	145.64	-	99
Current Portion of Long-Term Debt	392.2	8.95	7.84	-	-
Current Portion of Leases	58.99	149.63	142.07	38.42	124.84
Current Income Taxes Payable	-	379.45	261.61	260.73	378.84
Current Unearned Revenue	283.9	494.9	940.5	645.75	745.17
Other Current Liabilities	6,148	5,812	1,333	1,346	1,258
Total Current Liabilities	9,634	10,183	8,958	7,226	6,302
Long-Term Debt	-	-	28.95	-	-
Long-Term Leases	56.14	107.06	258.04	55.62	92.88
Long-Term Unearned Revenue	-	340.53	270.92	250.2	253.97
Long-Term Deferred Tax Liabilities	424.73	574.84	611.99	381.48	320.44
Other Long-Term Liabilities	407.81	59.16	-	-	-
Total Liabilities	10,523	11,264	10,128	7,913	6,969
Common Stock	11,033	10,899	10,899	10,899	10,899
Additional Paid-In Capital	-	390.53	196.57	46.79	46.79
Retained Earnings	-	26,245	23,192	19,188	15,197
Treasury Stock	-	-316.21	-83.71	-85.6	-100.71
Comprehensive Income & Other	21,232	-4,015	-4,006	-4,062	-3,710
Total Common Equity	32,265	33,203	30,198	25,987	22,332
Minority Interest	1,602	1,815	1,444	841.56	768.79
Shareholders' Equity	33,866	35,018	31,642	26,828	23,101
Total Liabilities & Equity	44,389	46,282	41,770	34,742	30,070
Total Debt	507.33	706.9	582.54	94.04	316.71
Net Cash (Debt)	7,577	13,058	13,984	11,213	8,999
Net Cash Growth	-41.98%	-6.62%	24.70%	24.61%	61.43%
Net Cash Per Share	0.65	1.10	1.17	0.94	0.75
Filing Date Shares Outstanding	11,566	11,852	11,917	11,918	11,955
Total Common Shares Outstanding	11,566	11,852	11,917	11,918	11,955
Working Capital	12,254	16,562	14,999	13,110	9,620
Book Value Per Share	2.79	2.80	2.53	2.18	1.87
Tangible Book Value	29,420	30,822	28,090	25,411	21,688
Tangible Book Value Per Share	2.54	2.60	2.36	2.13	1.81
Buildings	-	5,389	4,639	4,135	3,569
Machinery	-	9,194	7,317	6,723	5,961
Construction In Progress	-	1,246	2,245	1,534	1,483

Updated Nov 15, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.